Media Contact

Contact

Contact-image
Address:
Chris Hagerman, Investor Relations WS

OxySure Therapeutics, Inc. (Ticker: OXYS)

10880 John W. Elliott Road,
Suite 600
Frisco, TX 75033 USA
Tel: (+1)208-361-6624
Website: www.oxysure.com
Email: media@oxysure.com

FDA approval number: K052396
FDA Establishment Registration number: 3004167951
FDA Owner/Operator number: 10023108
Texas Department of Health Authorization Number: 823744
General Services Administration (GSA) Contract number: V797P4153B
Common Stock CUSIP number: 69208T 101

Contact Form

Send an email. All fields with an * are required.

Other information

Other information:

 

 

Media Relations

OxySure Therapeutics, Inc. (Ticker: OXYS)

10880 John W. Elliott Road, Suite 600

 Frisco, TX 75033 USA

 Tel: (+1) 972-294-6450

  Email: jamespr@oxysure.com

 

Other Company Information

  FDA approval number: K052396

 FDA Establishment Registration number: 3004167951

 FDA Owner/Operator number: 10023108

 Texas Department of Health Authorization Number: 823744

General Services Administration (GSA) Contract number: V797P4153B

 Common Stock CUSIP number: 69208T 101